# SomaLogic and Novartis sign ten-year proteomics agreement

SomaLogic has entered into a new ten-year agreement with Novartis to expand the use of its SomaScan proteomic platform across Novartis's drug development, including analysis of at least 250,000 clinical samples.

- Type: Contract
- Announced: 2019-10-21
- Status: announced
- Products: proteomic technology, SomaScan Platform
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novartis](https://endata.com/companies/32041.md) (customer)
- [SomaLogic](https://endata.com/companies/42821.md) (supplier)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2019/10/21/1932493/0/en/SomaLogic-Significantly-Expands-Key-Strategic-Collaboration.html), 2019-10-21: "SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.